Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(8 years from now) | |
US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
US11667673 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(10 years from now) | |
US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(10 years from now) | |
US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(10 years from now) | |
US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(12 years from now) | |
US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(15 years from now) |
Tibsovo is owned by Servier.
Tibsovo contains Ivosidenib.
Tibsovo has a total of 10 drug patents out of which 0 drug patents have expired.
Tibsovo was authorised for market use on 20 July, 2018.
Tibsovo is available in tablet;oral dosage forms.
Tibsovo can be used as a method for treating newly diagnosed aml characterized by the presence of a mutant allele of idh1 selected from r132h, r132c, r132l, r132v, r132s and r132gf by administering ivosidenib and azacitidine, a method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation, treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal, a method for treating aml by administering a pharmaceutical composition comprising ivosidenib wherein the aml is newly diagnosed and characterized by a mutant idh1 and the composition is administered in combination with azacitidine, a method of treating a cancer characterized by an idh1 mutation wherein the cancer is previously treated, locally advanced or metastatic cholangiocarcinoma, a method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg), a method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory, a method of treating a cancer characterized by an idh1 mutation wherein the cancer is relapsed or refractory myelodysplastic syndromes.
Drug patent challenges can be filed against Tibsovo from 20 July, 2022.
The generics of Tibsovo are possible to be released after 07 June, 2039.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
New Indication(I-875) | Aug 25, 2024 |
New Indication(I-924) | Oct 24, 2026 |
Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
New Indication(I-893) | May 25, 2025 |
New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
New Indication(I-816) | May 02, 2022 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg); A method of treati...
Dosage: TABLET;ORAL